Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study
Vilaseca, Antoni, Guerrero, Félix, Zainfeld, Daniel, Shore, Neal D., Rodriguez Faba, Oscar, Meijer, Richard P., Witjes, Alfred Alfred, McRee, Autumn Jackson, Kalota, Anna, Stone, Nicole L., Lauring, Josh David, Zhu, Wei, Beeharry, Neil, O'Dondi, Lang A, Jayram, Gautam
Published in Journal of clinical oncology (20.02.2023)
Published in Journal of clinical oncology (20.02.2023)
Get full text
Journal Article
MP13-17 SUNRISE-2: A PHASE 3, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY OF TAR-200 IN COMBINATION WITH CETRELIMAB VERSUS CONCURRENT CHEMORADIOTHERAPY IN PARTICIPANTS WITH MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
Williams, Stephen, Cutie, Christopher, Keegan, Kirk, Raybold, Bradley, Stewart, Rachel, Acharya, Milin, Zhu, Wei, Li, Xiang, O'Dondi, Lang, Beeharry, Neil, Spratt, Daniel
Published in The Journal of urology (01.09.2021)
Published in The Journal of urology (01.09.2021)
Get full text
Journal Article
A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder
Williams, Stephen B., Cutie, Christopher, Keegan, Kirk A, Raybold, Bradley, Acharya, Milin, Zhu, Wei, Li, Xiang, O'Dondi, Lang A, Beeharry, Neil, Spratt, Daniel Eidelberg
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article